These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 27028734)

  • 41. Abnormal Heavy/Light Chain Ratio and Matched Pair Suppression Increase Residual Disease Detection Sensitivity in Patients With Multiple Myeloma With Deep Responses.
    Miyazaki K; Suzuki K
    Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):293-296. PubMed ID: 29472112
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma.
    Quach H; Benson S; Haysom H; Wilkes AM; Zacher N; Cole-Sinclair M; Miles Prince H; Mollee P; Spencer A; Joy Ho P; Harrison SJ; Lee C; Augustson B; Daly J
    Intern Med J; 2018 Feb; 48(2):210-220. PubMed ID: 29415351
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
    de Weers M; Tai YT; van der Veer MS; Bakker JM; Vink T; Jacobs DC; Oomen LA; Peipp M; Valerius T; Slootstra JW; Mutis T; Bleeker WK; Anderson KC; Lokhorst HM; van de Winkel JG; Parren PW
    J Immunol; 2011 Feb; 186(3):1840-8. PubMed ID: 21187443
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Monoclonal plasmocytic myeloma with 2 paraproteins, IgG kappa and IgG lambdal].
    Villiamey J; Bouvet JP; Di Menza C; Boccara M
    Nouv Presse Med; 1974 Dec; 3(45):2707-11. PubMed ID: 4142506
    [No Abstract]   [Full Text] [Related]  

  • 45. Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.
    Moreau P; van de Donk NW; San Miguel J; Lokhorst H; Nahi H; Ben-Yehuda D; Cavo M; Cook G; Delforge M; Einsele H; Zweegman S; Ludwig H; Driessen C; Palumbo A; Facon T; Plesner T; Dimopoulos M; Sondergeld P; Sonneveld P; Mateos MV
    Drugs; 2016 May; 76(8):853-67. PubMed ID: 27113582
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interference of monoclonal antibody therapies with serum protein electrophoresis tests.
    McCudden CR; Voorhees PM; Hainsworth SA; Whinna HC; Chapman JF; Hammett-Stabler CA; Willis MS
    Clin Chem; 2010 Dec; 56(12):1897-9. PubMed ID: 20940329
    [No Abstract]   [Full Text] [Related]  

  • 47. [Evaluation of the new Hevylite™ IgA assay for the diagnosis and follow-up of monoclonal gammopathies].
    Lakomy D; Lemaire-Ewing S; Denimal D; Bastie JN; Lafon I; Caillot D
    Ann Biol Clin (Paris); 2013; 71(2):157-63. PubMed ID: 23587579
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Detection and identification of serum monoclonal immunoglobulin by immunoisoelectric focusing. Limits of sensitivity and use during relapse of multiple myeloma.
    Sinclair D; Kumararatne DS; Stott D
    J Clin Pathol; 1984 Mar; 37(3):255-62. PubMed ID: 6421894
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma.
    Sanchez L; Wang Y; Siegel DS; Wang ML
    J Hematol Oncol; 2016 Jun; 9(1):51. PubMed ID: 27363983
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evusheld, a SARS-CoV-2 spike protein-directed attachment inhibitor, appears in serum protein electrophoresis and immunofixation: a case study.
    Shah SK; Hagrass HA
    Lab Med; 2023 Nov; 54(6):e201-e203. PubMed ID: 37707512
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.
    Nijhof IS; Lammerts van Bueren JJ; van Kessel B; Andre P; Morel Y; Lokhorst HM; van de Donk NW; Parren PW; Mutis T
    Haematologica; 2015 Feb; 100(2):263-8. PubMed ID: 25510242
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma.
    Laubach JP; Paba Prada CE; Richardson PG; Longo DL
    Clin Pharmacol Ther; 2017 Jan; 101(1):81-88. PubMed ID: 27806428
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Correlations among different markers determined by immunochemical methods used for the diagnosis and monitoring of intact immunoglobulin multiple myeloma cases.
    Dogaru M; Lazăr V; Coriu D
    Roum Arch Microbiol Immunol; 2012; 71(4):183-200. PubMed ID: 23755700
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
    Kang SY; Suh JT; Lee HJ; Yoon HJ; Lee WI
    Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antibodies contained in "M" component of some patients with multiple myeloma are directed to food antigens?
    Juranić Z; Radic J; Konic-Ristic A; Jelic S; Besu I; Mihaljevic B
    Leuk Res; 2006 Dec; 30(12):1585-6. PubMed ID: 16516966
    [TBL] [Abstract][Full Text] [Related]  

  • 56. When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy.
    Oostendorp M; Lammerts van Bueren JJ; Doshi P; Khan I; Ahmadi T; Parren PW; van Solinge WW; De Vooght KM
    Transfusion; 2015 Jun; 55(6 Pt 2):1555-62. PubMed ID: 25988285
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quantitation of serum free light chains does not compensate for serum immunofixation only when screening for monoclonal gammopathies.
    Böer K; Deufel T
    Clin Chem Lab Med; 2009; 47(9):1109-15. PubMed ID: 19728853
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Detection of a monoclonal antibody therapy (ofatumumab) by serum protein and immunofixation electrophoresis.
    Genzen JR; Kawaguchi KR; Furman RR
    Br J Haematol; 2011 Oct; 155(1):123-5. PubMed ID: 21521182
    [No Abstract]   [Full Text] [Related]  

  • 59. Differences identified between serum and urine immunofixation electrophoresis.
    Tracy E; Andrews DM; Constantin MA; Zhu Y
    Clin Chim Acta; 2015 Jan; 439():68-70. PubMed ID: 25307209
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients With Relapsed or Refractory Multiple Myeloma.
    Chari A; Arinsburg S; Jagannath S; Satta T; Treadwell I; Catamero D; Morgan G; Feng H; Uhlar C; Khan I; Doshi P; Usmani S
    Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):44-51. PubMed ID: 29054515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.